Convertible Notes Offering

Healthcare
Convertible Notes Offering

Summary

Baird served as co-manager on this offering

About

NanoString Technologies, Inc. (“NanoString” or the “Company”) (NASDAQ:NSTG) recently completed an upsized offering pursuant to Rule 144A of $200 million aggregate principal amount of 2.625% Convertible Senior Notes due 2025. In addition, NanoString has granted to the initial purchasers of the notes a 13-day option to purchase up to an additional $30 million aggregate principal amount of notes.

NanoString is a leading provider of life science tools for translational research. The Company’s nCounter® Analysis System is used in life sciences research and has been cited in more than 3,200 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The Company’s GeoMx™ Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. NanoString is headquartered in Seattle, Washington.
CONTACT US TO LEARN MORE
Healthcare
Convertible Notes Offering
Date
March 2020
Company
NanoString Technologies, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share